论文部分内容阅读
目的探讨重组人白细胞介素-11(rhIL-11)对急性白血病化疗所致的血小板减少的疗效。方法26例急性白血病,采用自身对照研究,给予常规和大剂量化疗,化疗联合rhIL-11治疗,观察患者的血小板计数变化、输注血小板的剂量及药物的不良反应。结果两组联合rhIL-11治疗与未联合rhIL-11相比,血小板恢复时间、血小板上升最高值及输注血小板悬液的量差异均有统计学意义(P<0.05);在联合rhIL-11治疗中,常规组与大剂量组相比,血小板上升最高值差异无统计学意义,输注血小板的量及血小板恢复时间差异有统计学意义(P<0.01)。结论急性白血病化疗后应用rhIL-1l可促进血小板的生成,减少血小板悬液的输注,降低因化疗后血小板减少引起出血的风险。
Objective To investigate the effect of recombinant human interleukin-11 (rhIL-11) on thrombocytopenia induced by chemotherapy in acute leukemia. Methods Twenty-six patients with acute leukemia were enrolled in this study. Patients were given routine and high-dose chemotherapy and rhIL-11 combined with chemotherapy. The changes of platelet count, platelet transfusion dose and drug adverse reactions were observed. Results Compared with rhIL-11, the time of platelet recovery, the highest value of platelet rise and the volume of platelet transfusion in both rhIL-11 treated and untreated rhIL-11 groups were significantly different (P <0.05) There was no significant difference in the maximum value of platelet uptake between conventional group and high dose group during the treatment. The amount of platelet transfused and platelet recovery time had significant difference (P <0.01). Conclusion The application of rhIL-1l after acute leukemia can promote platelet production, reduce the transfusion of platelet suspension and reduce the risk of bleeding caused by thrombocytopenia after chemotherapy.